The prescribing of cardioprotective medications and the impact on survival for patients with peripheral artery disease that undergo intervention

Abstract

AbstractBackgroundCardiovascular disease guidelines recommend that patients with established peripheral artery disease (PAD) are prescribed antihypertensive, lipid‐lowering, and antiplatelet medication to reduce cardiovascular ischaemic events. However, the prescribing of these medications for patients with PAD within New Zealand (NZ) remains undefined.MethodsThis was a retrospective observational cohort study of patients in the Midland region of NZ, that underwent PAD‐related percutaneous and surgical intervention between 1st January 2010 and 31st December 2021. Patient level data was collected. The primary outcome was prescribing of cardioprotective medications either before or within 1 year of incident procedure. Secondary outcome was overall survival.ResultsThere were 2547 patients included. Antihypertensive prescription occurred in 80.7%, lipid‐lowering in 77.4% and antithrombotic in 89.9%. Concomitant ischaemic heart disease increased prescription of cardioprotective medications. Women were prescribed less lipid‐lowering medication compared to men. Māori men were prescribed less antiplatelet medication compared to non‐Māori men. On univariate analysis lipid‐lowering and antiplatelet medication showed survival advantage, while antihypertensive and anticoagulation did not. After adjustment for age, sex, end stage renal failure and presence of chronic limb‐threatening ischaemia, best medical therapy was associated with better survival (HR 0.88, 95% CI 0.79–0.98, P = 0.02).ConclusionThis study highlights areas of deficiency in prescribing of cardioprotective medication in this high‐risk group. These could be targets for national quality improvement initiatives.